Essential TremorELECTRE2NCT02052271
Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
A study testing Cathodal cerebellar transcranial direct current active stimulation in people with Essential Tremor, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Essential Tremor
- What is being tested?
- Cathodal cerebellar transcranial direct current active stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteFrance
- Study dates
- 3 Jun 2014to 27 Mar 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years and ≤ 65 years
- Important essential tremor (bilateral postural and/or action tremor since more than one year)
- Normal physical and neurological examination, except for essential tremor
- Insufficient efficiency of usual essential tremor's treatment
- No treatment altering the cortical excitability
- Agreement to use a medically acceptable method of contraception throughout the study for female of childbearing potential
- mini-mental status score >24
Who cannot join
- Age < 18 years and > 65 years
- Current neurological or psychiatric illness other than essential tremor
- Individual who is on medication which is known to lower seizure threshold
- Previous history of seizure, loss of conciousness or current active epilepsy
- Contraindication for MRI or TMS study
- Intake of antiepileptic medications for essential tremor (barbiturates, gabapentine, topiramate, clonazepam), within the 7 days preceeding the first visit
Show all 11Show fewer
- alcohol intake within the 24 hours preceeding the first visit
- Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
- Individual who have MMS ≤ 24/30 or patients legally protected or inability to provide an informed consent
- Simultaneous participation in another clinical trial
- Patients who are not enrolled at social security
Trial locations and contacts
1 site in 1 country.
France1 site
Institut du Cerveau et de la Moelle, Hôpital Pitié-Salpétrière
Paris, 75651
About this study
Official title: Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Transcranienne Par Courant Direct (tDCS) du Cortex Cerebelleux
The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor.
- Conditions
- Essential Tremor
- Being tested
- Cathodal cerebellar transcranial direct current placebo stimulation, Cathodal cerebellar transcranial direct current active stimulation
- Keywords
- essential tremor, cerebellum, transcranial direct current stimulation, electrophysiology
- Medical subject headings
- Essential Tremor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cathodal cerebellar transcranial direct current placebo stimulationDevice
Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
Cathodal cerebellar transcranial direct current active stimulationDevice
Active stimulation: duration: 20 mn, intensity: 2 mA; localisation cerebellum;
| Study group | Role | What they receive |
|---|---|---|
| Essential tremor | Experimental | cerebellar stimulation Receives: Device: Cathodal cerebellar transcranial direct current active stimulation |
| Placebo arm | Placebo comparator | placebo stimulation Receives: Device: Cathodal cerebellar transcranial direct current placebo stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in tremor amplitude on clinical rating scale
Measured: 10 minutes after the end of tDCS
Secondary outcomes (5)
Change from baseline in tremor amplitude on accelerometric recording
Measured: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on electromyographic recordings
Measured: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on digitized tablet
Measured: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on clinical rating scale
Measured: During tDCS, 60 mn and 90 mn after the end of tDCS
Change from baseline of amplitude of motor evoked potentials elicited by TMS
Measured: 10 mn, 60 mn and 90 mn after tDCS
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2014 (estimated)
- Study start3 Jun 2014
- Primary completion27 Mar 2018
- Study completion27 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Essential TremorStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Emmanuel Flamand-Roze, MD, Principal investigator, Institut du Cerveau et de la Moelle et Fédération de Neurologie de l'Hôpital Pitié-Salpétrière, Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02052271
- Sponsor's protocol ID
- C13-24
- Other IDs
- 2013-A01404-41
- Acronym
- ELECTRE2
- Status last verified
- Feb 2020
- First submitted
- 28 Jan 2014
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Transcranienne Par Courant Direct (tDCS) du Cortex Cerebelleux
- ClinicalTrials.gov ID
- NCT02052271
- Acronym / sponsor ID
- ELECTRE2 / C13-24
- Conditions
- Essential Tremor
- Keywords
- essential tremor, cerebellum, transcranial direct current stimulation, electrophysiology
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Study start
- 3 Jun 2014 (actual)
- Primary completion
- 27 Mar 2018 (actual)
- Study completion
- 27 Mar 2018 (actual)
- First posted
- 3 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Essential tremor | Experimental | Device: Cathodal cerebellar transcranial direct current active stimulationcerebellar stimulation |
| Placebo arm | Placebo comparator | Device: Cathodal cerebellar transcranial direct current placebo stimulationplacebo stimulation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 18 years and ≤ 65 years
- Important essential tremor (bilateral postural and/or action tremor since more than one year)
- Normal physical and neurological examination, except for essential tremor
- Insufficient efficiency of usual essential tremor's treatment
- No treatment altering the cortical excitability
Key exclusion criteria (11 listed)
- Age < 18 years and > 65 years
- Current neurological or psychiatric illness other than essential tremor
- Individual who is on medication which is known to lower seizure threshold
- Previous history of seizure, loss of conciousness or current active epilepsy
- Contraindication for MRI or TMS study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cathodal cerebellar transcranial direct current placebo stimulationPlacebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum; | Device | Placebo arm |
| Cathodal cerebellar transcranial direct current active stimulationActive stimulation: duration: 20 mn, intensity: 2 mA; localisation cerebellum; | Device | Essential tremor |
Primary outcome
Change from baseline in tremor amplitude on clinical rating scale
Time frame: 10 minutes after the end of tDCS
5 secondary outcomes
Change from baseline in tremor amplitude on accelerometric recording
Time frame: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on electromyographic recordings
Time frame: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on digitized tablet
Time frame: During tDCS, 10 mn, 60 mn and 90 mn after the end of tDCS
Change from baseline in tremor amplitude on clinical rating scale
Time frame: During tDCS, 60 mn and 90 mn after the end of tDCS
Change from baseline of amplitude of motor evoked potentials elicited by TMS
Time frame: 10 mn, 60 mn and 90 mn after tDCS
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Related trials for Essential Tremor
Active, not recruitingObservational study
Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor
Essential Tremor
RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Upper Limb Essential Tremor
Recruiting
Deep Brain Stimulation Surgery for Movement Disorders
Parkinson's Disease, Essential Tremor
RecruitingObservational study
Phenotype/Genotype Correlations in Movement Disorders
Movement Disorder
RecruitingObservational study
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Essential Tremor, Movement Disorders, Essential Tremor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emmanuel Flamand-Roze, MD principal investigator
Institut du Cerveau et de la Moelle et Fédération de Neurologie de l'Hôpital Pitié-Salpétrière, Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cathodal cerebellar transcranial direct current active stimulation in people with Essential Tremor, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in tremor amplitude on clinical rating scale (time frame: 10 minutes after the end of tDCS). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026; AzTrials last refreshed its copy on 2 Nov 2026.